Key Takeaways
- Investment in crop genomics is rotating away from corn and soybeans toward wheat and rice — crops central to global food security.
- The strategic objective has shifted from ‘convenience traits' like herbicide tolerance to ‘survival traits' such as drought and flood resilience.
- Regulatory approvals, including Syngenta's X-Terra® hybrid wheat in France, signal commercial viability for genomically-enhanced staple crops.
- India's release of 31 new rice varieties in 2025 reflects a dual-track strategy combining biofortification with climate resilience.
- Tool-sharing arrangements, such as Pairwise licensing its Fulcrum® platform to IRRI, are expanding crop genomics reach into smallholder markets.
A Reallocation of Genomic Capital
For the better part of two decades, the commercial logic of crop genomics pointed in one direction: corn and soybeans. The two crops offered industrial scale, an established trait market built around herbicide tolerance and insect resistance, and a concentrated buyer base in large-scale commodity agriculture. Genomic R&D investment followed this logic reliably.
The data from the first quarter of 2026 indicates that this concentration is breaking down. Capital and scientific attention in crop genomics are rotating toward wheat and rice — the crops that feed the majority of the world's population — and the strategic objectives driving that rotation are different in character from what drove the corn and soy era.
Crop Genomics and the ‘Survival Trait' Agenda
From Farming Ease to Climate Resilience
The distinction being drawn in the sector is between ‘convenience traits' and ‘survival traits.' The herbicide tolerance and insect resistance traits that defined the first generation of crop genomics investment were primarily designed to make farming easier and more economically efficient. The traits being prioritised in wheat and rice development in 2025 and 2026 are designed to keep crops viable in conditions that are becoming less predictable.
